Loading clinical trials...
Loading clinical trials...
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumo...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Chugai Pharmaceutical
NCT04570423 · Solid Tumors, Lymphoma
NCT06926283 · Prostate Cancer, Other Solid Tumors, and more
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT07489378 · Very Rare Tumors, Very Rare Cancers, and more
NCT07181681 · Solid Tumors, Advanced Solid Tumor
Washington D.C., District of Columbia
Tampa, Florida
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions